{"prompt": "['CIP HD01-16-30', 'HHELSINN', 'Version 1.0, 06/02/2017', '5. Objectives and hypotheses of the clinical investigation', '5.1', 'Primary Objective', 'The primary objective of this clinical investigation is to evaluate the proportion of patients without G2', 'radiation dermatitis at week 5.', '5.2', 'Secondary Objectives', 'The secondary objectives of this clinical investigation are:', '1. to evaluate the median time to G2 radiation dermatitis development according to CTCAE', '2. to evaluate the proportion of patients without G2 radiation dermatitis at week 6 for both cancer', 'sites, at week 7 for head & neck cancer and two weeks after the last radiation for both cancer', 'sites', '3. to evaluate the worst skin toxicity during treatment and until 2 weeks after the last radiation,', 'according to CTCAE', '4. to evaluate changes in skin erythema and pigmentation and trans-epidermal water loss (TEWL)', '5. to evaluate the mean and worst score of Patient Reported Outcome (PRO) with Skindex-16', 'questionnaire performed weekly', '6. to evaluate the compliance to experimental treatment use', '7. to evaluate the patient global satisfaction with treatment as assessed by Likert scale.', '5.3', 'Tolerability and safety objectives', 'The study product safety and tolerability will be evaluated.', '6. Design of the clinical investigation', '6.1 General', 'This is a monocenter, open label, randomized, standard of care controlled, post-marketing clinical', 'investigation.', 'Subjects will be randomly allocated to one of the following groups:', '-', 'Group A: Xonrid\u00ae gel + standard of care (SOC) preemptive treatment according to MASCC', 'guidelines;', '-', 'Group B: standard of care (SOC) preemptive treatment according to MASCC guidelines.', 'CONFIDENTIAL', 'Page 16 of 53']['CIP HD01-16-30', 'HHELSINN', 'Version 1.0, 06/02/2017', 'Both Groups will start treatments on the first day of radiotherapy and will go on until two weeks after', 'the last radiotherapy session.', \"Group B subjects will receive an additional standard treatment (according to Investigator's opinion) at\", 'G2 skin toxicity development.', 'All subjects will interrupt the treatment and the study in the case of G3 skin toxicity development. Should', \"this occur, the subject will be treated according to the Investigator's opinion.\", 'Each patient for whom written consent is obtained will be assigned a five-digit screening code, consisting', 'of the cancer area (e.g. 01 = head & neck; 02= breast) and a progressive number within the site: for', 'example the first subject screened for head & neck cancer will be assigned the code 01-001, the second', 'one 01-002 etc.; the first subject screened for breast cancer will be assigned the code 02-001, the second', 'one 02-002 etc.', 'All screened subjects will receive the code irrespective of whether or not they will be randomized. If a', 'subject discontinues from the study at any time, the code will not be re-used.', 'All subjects who will sign the informed consent and receive the screening code will be entered into a', \"Subject's Register, containing the name and surname of the patients and the date they have signed the\", 'consent form.', 'Eligible patients will be randomized to receive the treatment according to a randomization list.', 'The patient randomization list will be generated by Latis S.r.l., using the PROC PLAN of SAS 9.4 for', 'Windows (SAS Institute Inc., Cary, NC, USA). Once eligibility of a patient is established (see', 'Inclusion/Exclusion Criteria) the study treatment will be assigned through centralized randomization', 'system.', \"The Investigator will also keep record of all enrolled patients in the Subject's Enrolment Log: the subject\", 'screening number, the date of consent, the treatment assigned to the patient, if applicable, or the', 'reason for not being randomized will be recorded.', '6.2', 'Investigational device and comparator', '6.2.1 Xonrid', 'The product under investigation is Xonrid', 'Name: Xonrid', 'Formulation: Gel', 'Route of administration: Topical', 'CONFIDENTIAL', 'Page 17 of 53']['CIP HD01-16-30', 'HHELSINN', 'Version 1.0, 06/02/2017', 'Composition: the composition of Xonrid, including ingredient function, as reported in the commercial', 'available product, is reported in Table 4.', 'Xonrid is a short term use, Class Ila Medical Device, a topical gel designed for RT-induced dermatitis.', 'When applied to the target skin areas, Xonrid forms a protective film, reduces the trans-epidermal water', 'loss (TEWL) effect induced by external factors and increases moisturizing. The component responsible for', 'the formation of this film is mainly Hyaluronic Acid, that also helps to achieve an optimal moisturizing', 'effect. The other components responsible for the formation of this film are: polyacrylamide', 'gluconolactone, and Xanthan gum. In particular, gluconolactone is a polyhydroxy acid, with a strong', 'hygroscopic moisturizing power, as well as a glycerin effect. Moreover, the device includes sweet almond', 'oil, known for its emollient, softening, nourishing and soothing properties, and is particularly effective in', 'the treatment of dry, reddened and sensitive skin areas. It promotes the healing process by restoring the', 'physiological hydration levels of the affected skin areas. It can be applied to the target areas including', 'skin folds and creases, either presenting or not minor traumas or abrasions. On these bases, Xonrid may', 'represent a promising device for the prevention of radiation dermatitis.', 'Table 4: Xonrid ingredients with relative function', 'Ingredient', 'Function', 'Glycerin (Glycerol)', 'Humectant', 'Gluconolactone, sodium benzoate, calcium gluconate', 'Preservative', 'Chamomilla recutita water', 'Masking agent', 'Xanthan gum', 'Rheology additive', 'C12-15 alkyl benzoate', 'Emollient', 'Ethylhexyl palmitate', 'Emollient', 'Disodium EDTA', 'Chelanting agent', 'Glyceryl stearate', 'Emollient', 'Prunus amygdalus dulcis oil', 'Emollient', 'Polyacrylamide, C13-14 isoparaffin, laureth-7', 'Viscosity increasing agent', 'Vitis vinifera extract, aqua, propylene glycol', 'Skin conditioning agent', 'Aqua', 'Solvent', 'Sodium hyaluronate', 'Skin conditioning agent', 'Propylene glycol, aqua, camelia sinensis extract', 'Skin conditioning agents', 'Propylene glycol, hydrolyzed RNA, hydrolyzed DNA', 'Skin conditioning agents', 'CONFIDENTIAL', 'Page 18 of 53']\n\n###\n\n", "completion": "END"}